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Association of environmental tobacco smoke at 
work and forced expiratory lung function among 
never smoking asthmatics and non-asthmatics 
Studies on long-term effects of ex- 
posure to environmental tobacco 
smoke (ETS) on pulmonary func- 
tion show impaired lung function in 
children but inconsistent results 
among adults 1-4. The contradictory 
findings among adults may indicate 
that ETS has no or very little effect 
on lung function. Other explana- 
tions relate to methodological is-
sues such as differences in the level 
of exposure, incomparable selec- 
tion and measurement procedures 
across studies, or uncontrolled cu- 
mulative burden of other respira- 
tory insults among adults 2. Fur- 
thermore, pidemiologic studies on 
ETS might be affected by self- 
selection bias, if subjects prevent 
ETS exposure for health reasons. 
This bias will be particularly strong 
assessing the impact of ETS ex- 
posure at home which is easier to 
influence than ETS exposure at 
work or elsewhere. 
Apart from biases, disparate re- 
suits may also be expected if sus- 
ceptibility to ETS were heteroge- 
neous within populations. If ETS 
affects ubgroups only, the average 
effect in the general population 
may be diluted, depending on the 
proportion of susceptible. An ade- 
quate approach to deal with this 
problem would be to focus inves- 
tigations on susceptible subjects. 
Increased susceptibility has been 
suggested for asthmatics ~ . How- 
ever, epidemiological studies on 
chronic effects of ETS often exclu- 
ded asthmatics 6-8 or did not report 
on this group specifically 9-12. Jindal 
et al. reported increased morbidity 
and lower lung function values 
among ETS exposed asthmatics as 
compared to non-exposed asthma- 
tics13. A similar marker of suscep- 
tibility may be hyperreactive air 
ways 14,15. No other markers of 
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susceptibility for ETS have been 
identified, although suggestions 
have been made that the impact of 
ETS may differ depending on the 
ethnic background or across ex 16. 
In a first report from the large ran- 
dom population of the Swiss 
Study on Air Pollution and Lung 
Disease in Adults (SAPALDIA) 
we showed significant associations 
of ETS with the prevalence of 
respiratory symptoms 17. The pur- 
pose of this analysis is to assess the 
association of ETS exposure with 
pulmonary function. We will parti- 
cularly address whether the as- 
sociation of ETS with pulmonary 
function varies by asthma status 
and/or sex as suggested markers of 
susceptibility. To limit biases and to 
improve the efficiency of this study 
we follow three strategies. First, we 
restrict on life-time never smokers. 
Second, we exclusively focus on 
ETS exposure at work rather than 
at home, given ETS at home to be 
more likely to be subject o uncon- 
trolled self-selection. This might be 
particularly the case among ETS 
susceptible asthmatics. Third, we 
do not only use measures of lung 
volume (FVC and FEV1) as health 
endpoints but include mid-expira- 
tory flow measures (FEF25-75 %) 
which are more specific for changes 
in the small airways, where the ear- 
liest effects may occur  18-2~ 
Materials and methods 
Study population 
This analysis is based on life-time 
never smoking participants of 
SAPALDIA with acceptable and 
reproducible forced expiratory 
lung function assessment 2~.SA- 
PALDIA is a multi-centre study 
to evaluate the relationship be- 
tween environmental factors and 
respiratory symptoms and disease. 
Eight areas in Switzerland were 
chosen to represent a range of 
urbanization, altitude, air pollu- 
tion, and meteorology2L Random 
samples of adults (N = 17300), 
aged 18-60 years, were drawn 
from the registries of residents in 
each location. Successfully recruit- 
ed subjects (59%) were asked on 
respiratory health and symptoms, 
active and passive smoking expo- 
sure, and spirometric examinations 
and allergy tests were performed. 
A total of 9651 subjects completed 
the questionnaire interview and 
spirometry. Of them, 3534 yielded 
both acceptable pulmonary func- 
tion tests and a negative history of 
smoking at any time in life. Sam- 
pled persons who refused to par- 
ticipate were asked a shorter ques- 
tionnaire. Over 70% of the non- 
participants provided this infor- 
mation 23. 
Pulmonary function test 
Pulmonary function was measured 
according to published guidelines 21
with a computerized equipment 
(SENSORMEDICS 2200). At least 
three and up to eight manoeuvres 
were required in sitting position 
with nose clip. Spirometry quality 
control training and studies were 
conducted to evaluate systematic 
area specific errors and improve 
standardized assessment across 
teams and technicians 24. 
Bronchial reactivity was measured 
by the dosimeter method, using 
MEFAR nebulizers. The standard- 
ized procedure, identical to the 
short protocol of the European 
Community Respiratory Health 
Survey 25, consisted in one to five 
inhalation steps up to a cumulative 
dose of 2 mg methacholine or until 
FEV1 decreased at least 20% 
compared to baseline (PD20). 
Throughout this text, subjects with 
a PD20 up to 2 mg were defined as 
having "reactive airways". Par- 
ticipants with an FEV1 baseline 
measure below 70% predicted or 
an FEV1/FVC ratio below 80% 
predicted were excluded from the 
metchacholine challenge. 
Working definitions 
Those who had never smoked or 
smoked less than 20 packs of ci- 
garettes or less than 360 gram of 
tobacco in their entire life were 
defined as "never smokers". Ex- 
posure to other peoples moke was 
first asked for the last 12 months. 
We asked about the number of 
smokers exposed to at home, 
whether or not other people reg- 
ularly smoked at work, and total 
hours of ETS exposure per day, 
irrespective of location. The next 
set of questions addressed long- 
term history of ETS exposure, 
asking about the total number of 
both years of ETS exposure and 
the persons exposed. A last ques- 
tion assessed the subjective distur- 
bance due to ETS exposure, shown 
on a scale from 0 ("not at all") to 
10 (extremely disturbed). 
There is no single epidemiological 
definition of asthma 26. In the pre- 
sent analyses, "asthma" included 
those with a positive response to 
both questions: "Have you ever 
had asthma?" and "Was this con- 
firmed by a doctor?" or with a po- 
sitive answer to both questions: 
"Have you had wheezing or whist- 
ling in your chest at any time in 
the last 12 months?" and "Have 
you had this when you did not have 
a cold?". Major reasons to define 
this broader group were that asthma 
- a wheezing disease - not being 
uniquely defined, and considering 
"history of wheezing without cold 
in the last 12 months" to be a likely 
predictor for undiagnosed asthma 
in adults. The questionnaire cover- 
ed recent use of medication for 
asthma and other respiratory dis- 
eases. 
We will use the dichotomous result 
of the Phadiatop | test as measured 
in a blood sample to define atopic 
hypersensitivity (IgE mediated sen- 
sitization). 
Information on highest educa- 
tional level achieved was used to 




Forced expiratory pulmonary func- 
tion measures were used as de- 
pendent variables. Apart from the 
forced vital capacity, FVC, and the 
volume expired in the first second, 
FEV1, we particularly included 
mid-expiratory flow rates, FEF25- 
75 %, as they also reflect changes in 
the peripheral airways, where the 
first tobacco smoke related struc- 
tural changes may occur. Models 
were chosen such to not violate 
linear model assumptions regard- 
ing the distribution of residuals. To 
reduce heteroscedasticity of re- 
siduals across age, log-transformed 
lung function values were used. 
Inclusion of "age squared", in ad- 
dition to age, improved the fit of 
the model, given the age depen- 
dent plateau of pulmonary func- 
tion values in the third decade 27,28. 
ETS at work was used as binary 
variable. We adjusted on geograph- 
ic area, a surrogate for factors not 
included in the model but poten- 
tially related to lung function and 
ETS such as environmental airpol- 
lution, climate, or technical factors 
in lung function assessment 22,24. 
ETS exposure at home, gas/dust/ 
fume exposure at work, cooking 
with gas, educational level, report- 
ed mould at home within the last 
12 months, atopic status based on 
Phadiatop | , history of respiratory 
infection in childhood, ETS ex- 
posure in utero and during child- 
hood from mother and/or father 
and subjectiv.e annoyance l vels due 
to ETS were considered potential 
confounders, i.e. risk factors - or 
proxy measures for risk - of lung 
function decrement and possibly 
being associated with our exposure 
variable. 
Analyses were performed with 
SAS/STAT software on a main 
frame. The General Linear Model 
(GLM) procedure was used for 
the regressions. The non-param- 
etric data summary (Figure 1) was 
based on median smoothing lines 
with the software package STATA. 
o ETS  no  
6 
o ~ ETS  yes 
o o 
A ~8 o o 
4 ~oO o o 
~'1  8 o 0 o 
o o o o o 
o o o o 
P4 
III ~  o ~ ~E --~---z_. o ~ " ' ' '~ .L  ~ ~176176 
~ ~ A ~ oO ~ ~176 o&o ~ o 
o o o 
O 
I ~ I I I 
20 30  40  50  60  
Age at examinat ion (years)  
Figure 1. Observed FEF25-75% by age, among asthmatic women with 
bronchial reactivity or no participation in methacholine challenge; with ( A ) 
and without (o) ETS at work. (Definitions see text). (Overlaid are non-para- 
metric smoothing lines by ETS group, based on five median bands). 
Results 
Table 1 summarizes characteristics 
of the SAPALDIA participants, 
non-participants, and the non- 
smoking subgroup selected for 
these analyses. There was little 
difference in age across these sam- 
ples. Non-participants were more 
likely to be female, but less likely 
to be wheezers than participants. 
Females were over-represertted in 
our subsample due to their lower 
smoking prevalence. 
Table 2 summarizes univariate dis- 
tributions of major characteristics 
in the selected population, by gen- 
der and asthma status. In women, 
15% reported ETS exposure at 
work and 18 % at home. Males who 
were more likely to hold a full time 
job, had higher prevalence of ETS 
at work (22%) but lower prev- 
alence at home (12 %). Asthmatic 
Table I. Mean age and prevalence of characteristics among participants 
and non-participants of SAPALDIA and the sample as selected for this 
presen ta tion a 
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Variable Male 
no asthma asthma/ 
wheezing ~ 
(N = 1246) (N = 142) 
36,6 (12.1) 37.4 (t3.2) 
176.2 (6.8) 176,2 (6.8) 
Forced exNratory lung function: 
FVC (ml) 5352 (791) 5129 (895) b 
FEV! (ml) 4281 (67t) 3923 (876) b 
FEE25.75% (titers/sec) 4.]8 (1.3) 3.51 (1.4) b 
ETS annoyance score (0 = no at all.. t0 = intolerable) 4.8 (3.6) 5.2 (3.5) 
Atopy (= positive Phadiatop ~ test result) 406 (33 %) 93 (65 %) b 
Environmental tobacco smoke at work 262(21%) 37 (26 %) 
Environmental tobacco smoke at home t48(t2%) 23 (16%) 
Female 
1007(81%) 66 (48%) 
92 (7 %) 
147 (12 %) 
" Do~orS diagnos~ asthmaand/or wheezing w~thout cotd. 
< 2 b p_<0.05f~t4estorX ,respectively, comparingasthmati~heez!~gVers~s:n~ma~bmatic~with~ngender. 
c 2 0 ~ 0.05 for t-test or X ~. , respectively, comparing female versus male am0~g asthmatic/wheezing only. 
Table 2. Univariate distributions of population characteristics, asthmatic versus non-asthmatic subjects, by gender. 
SAPALDIA never smokers 1991. Mean values (and standard deviation) or number of subjects (and percent), 
respectively. 
men and women had lower lung 
function, increased prevalence of 
atopy and higher annoyance scores 
for ETS. 
Table 3 presents the percent change 
in lung function associated with 
ETS exposure at work. The main 
model indicated slightly lower 
FEV1 (-0.1%) and FEF25-75% 
(-1.9%) among those with ETS 
exposure at work. The coefficients 
were, however, not statistically sig- 
nificant nor was FVC associated 
with ETS (+ 0.7 %). Interaction 
terms of ETS with asthma status 
and sex were strongly significant, 
indicating the need for stratified 
analyses. Among asthmatics, the 
main model indicated a significant 
decrease of both FEV1 (-4.8%) 
and FEF25-75 % (- 12.4 % ) where- 
as the reduced FVC was not sta- 
tistically significant (-1.7 %). The 
interaction of ETS with sex re- 
mained again significant. In the 
stratified analyses, one can see 
that the aforementioned associa- 
tion with ETS was mostly due to 
the impact of ETS among asthmatic 
women, where FEV1 and FEF25- 
75 % were significantly lower 
among those exposed to ETS at 
work. In non-asthmatic women and 
in men with or without asthma, 
ETS was not associated with pul- 
monary function. 
Given the limitations of a ques- 
tionnaire based definition of "asth- 
ma", we used bronchial reactivity 
status for a more specific definition 
of asthma. As expected, signifi- 
cantly independent effects of ETS 
at work on FEV1 and FEF25-75 % 
were most pronounced among 
asthmatics with hyperreactive air- 
ways and non-participants of the 
bronchial challenge (Table 4). Non- 
participation i  the methacholine 
challenge, among asthmatics, was 
mostly due to obstructive pre-test 
conditions. In "asthmatics" with no 
reaction to methacholine, the co- 
efficients for ETS at work were 
not statistically significant. Again, 
among men, the coefficients were 
close to zero in all subgroups con- 
sidered in Table 4. 
The impact of ETS among the most 
susceptible women (asthmatic with 
hyperreactive airways) is present- 
ed in Figure 1, showing the decline 
of FEF25-75 % with age for both 
exposure groups. 
To test the sensitivity of the effects 
to the statistical modeling, we in- 
cluded a large set of potentially 
211 
Table 3. Percent change (and 95 % confidence intervals) in lung function measures associated with environmental 
tobacco smoke exposure at work. Main model for asthmatic ~ versus non-asthmatic, by gender. SAPALDIA never 
smokers 1991 b. 
Table 4. Percent change (and 95% confidence intervals) in FEV1 and FEF25-75 % associated with environmental 
tobacco smoke exposure at work. Main model for asthmatic women ~, by bronchial reactivity status. 5APALDIA 
never smokers 1991 b. 
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confounding covariates (see me- 
thods). The coefficients of ETS on 
pulmonary function showed very 
little increase or decrease in this 
sensitivity analysis. 
Dose-response 
Our questionnaire included quan- 
titative ETS measures, such as 
"hours per day exposed to ETS" 
(referring to the last 12 months) 
and total number of years. These 
questions, however, were not spe- 
cifically limited to ETS at work, 
compromising a direct dose-re- 
sponse assessment for ETS at work. 
Thus, we restricted the analyses on 
subjects with no ETS exposure at 
home, among which quantitative 
ETS measures are likely to reflect 
primarily ETS at work. Both, hours 
per day and number of years expo- 
sed to ETS were significantly relat- 
ed to decreased FEF25-75 % and 
FEV1 in asthmatic women but not 
in men and other groups. FEF25- 
75 % decreased by-3.4% per hour/ 
day (p<0.05) and -1% per year 
(p = 0.02). Results for FEV1 were 
-6%/hour (p = 0.01) and-1% per 
year (not significant), respectively. 
Among those exposed, 43% re- 
ported up to two hours per day; 
35 % indicated five or more hours 
of daily exposure. 
Discussion 
Our cross-sectional population- 
based study revealed significantly 
impaired lung function among 
asthmatic women reporting ETS 
exposure at work as compared to 
non-exposed. The impact was par- 
ticularly strong on FEF25-75% 
and FEV1 whereas for FVC the 
effect was small and did not reach 
statistical significance. 
The major strength of this study is 
its focus on susceptible subgroups. 
The analyses indicated that ETS 
exposure at work was associated 
with lower pulmonary function 
among asthmatics only. The inde- 
pendent effect of ETS was not con- 
founded by any available and 
potentially relevant covariate, in- 
cluding ETS exposure at home. 
Convincingly, the association was 
strongest in hyperreactive asthma- 
tics and those not participating in
the bronchial challenge. Inclusion 
of bronchial reactivity status can be 
considered an efficient approach 
to improve the specificity of our 
asthma working definition 26,29. In 
fact, our data showed non-reactive 
asthmatics tobe three to four times 
less likely to report recent use of 
beta mimetica than the other asth- 
matics (data not shown) and their 
lung function mean values were 
similar to those among non-asth- 
matic (Table 2, Table 4). The addi- 
tional independent decrement that 
was associated with ETS at work 
has to be considered relevant in a 
subgroup with already limited tung 
function. Our results are consistent 
with findings, comparing ETS ex- 
posed and unexposed asthmatics, 
age 15 to 5013 . The exposed group 
had higher morbidity indices and a 
15 % and 28 % significantly lower 
FEV1 and FEF25-75%, respec- 
tively. Furthermore, a recent cham- 
ber study confirmed acute effects 
of ETS on FEV1 among asthmatics 
but not in non-asthmatics 3~ 
The further focus on sex specific 
effects showed, however, that the 
effect observed among asthmatics 
was clearly driven by the effect 
in women with asthma, whereas 
among men, ETS was not asso- 
ciated with lower lung function 
values. Thus, the question arises 
whether female sex is a marker for 
susceptibility to ETS. The litera- 
ture gives no consistent evidence 
for female being at higher risk of 
ETS effects, although one may 
argue that smaller lungs and air- 
ways may partially explain differ- 
ential susceptibility 31.In our study, 
however, no significant interaction 
between ETS and lung size could 
be observed (not shown). Recently, 
Corbo et al. reported smoking and 
ETS to be more strongly related to 
COPD in women than in men, with 
particularly strong effects in atopic 
women3L Furthermore, if one may 
compare ETS with smoking, it is 
to emphasize that several studies 
conclude that the deleterious ef- 
fects of smoking are stronger in 
female, given the same amount 
smoked 33-35. 
Apart from the fact the statistical 
power was lower in men where 
sample sizes were 35% smaller 
than in female subgroups, the 
apparent sex difference of ETS 
effects may be explained by re- 
porting bias or by differences in 
the level of ETS exposure across 
gender. 
In the cross-sectional design, ques- 
tionnaire-based exposure assess- 
ment may be biased. Asthmatic 
women with hyperreactive airways 
were more likely to report ETS ex- 
posure at work then non-asthmatic 
(p = 0.05); no such difference was 
observed in male subgroups. In 
addition, hyperreactive asthmatic 
women without ETS at home re- 
ported higher number of hours of 
ETS exposure per day then the 
male comparison group (7.4h/d 
versus 4.3, p = 0.09; data not shown). 
We cannot directly assess whether 
this reflects higher ETS exposure, 
over reporting among hyperreac- 
tive female asthmatics, or limited 
awareness of ETS in mate asthma- 
tics and non-asthmatic subjects. 
Within strata of asthma history, the 
subjective annoyance score, asked 
for ETS in general, was slightly but 
not significantly higher in women 
(see Table 2). Furthermore, ETS 
was not much in public debate in 
Switzerland (1991) nor a specific 
focus of SAPALDIA which limits 
the problem of differential report- 
ing bias. Thus, the higher eporting 
of ETS exposure may reflect true 
differences inexposure rather than 
reporting bias. Asthmatic women 
held jobs of lower status, on aver- 
age, compared to men and might 
have been prone to increased ETS 
at work and crowding, combined 
with limited options to avoid ETS. 
Unfortunately, the study did not 
include an objective measure of 
long-term ETS exposure to con- 
firm our interpretation. However, 
the observed dose-response r la- 
tionship for ETS at work ("hours 
per day") among those not exposed 
to ETS at home strongly supports 
the notion of a true ETS effect in 
asthmatic. 
We conclude that differences inthe 
level of exposure may be the main 
reason for the observed sex pattern 
in our study whereas both, the lack 
of focus on susceptible subgroups 
and exposure differences may ex- 
plain discrepancies across other 
studies on ETS and lung function. 
White et al. reported significant 
13-14% lower FEF25-75% 
among women and men exposed 
to ETS at work 6. Inconsistencies 
between French and Dutch results 
on one side, confirming lower 
FEF25-75% among women aged 
40 or older a~,~2 and the negative US 
results 36 compared to the strongly 
positive study from China 37 were 
explained with potentially different 
life-style and housing conditions 
which may modify exposure. Hole 
et al., in a population cohort, repor- 
ted a significant 3.2 % lower FEV1 
when a cohabitee smoked >15 
cigarettes per day 38. Other studies 
with positive findings 7.9 or negative 
or unclear esults 8,1~ are based on 
not further specified volunteers, 
prone to uncontrolled selection 
bias. In a recent publication on 
the Seventh Day Adventist cohort, 
Abbey et al. observed lower lung 
function among ETS exposed men 
but not among women 39. The au- 
thors highlight that in their cohort, 
ETS exposure among women was 
lower than in men. In the future, 
molecular biomarkers may im- 
prove the power to establish effects 
of ETS on those truly susceptible. 
A recent presentation of yon 
Ehrenstein showed that the asso- 
ciation of ETS impaired lung func- 
tion among children was driven by 
the subgroup with low levels of 
alpha 1-Antitrypsin 40. 
In a cross-sectional design we can- 
not assess whether ETS exposure 
induced increased unspecific bron- 
chial reactivity or whether subjects 
with reactive airways are prone to 
ETS induced obstruction. Experi- 
mental studies are neither con- 
clusive on this issue. In an experi- 
ment undertaken by Danuser et al. 
comparing ten hyperreactive pa- 
tients with ten healthy controls, 
reactivity to side stream smoke and 
methacholine provocation were 
highly correlated TM. Knight re- 
ported that ETS might trigger 
attacks in asthmatics and that 
histamine reactivity was increas- 
ed four hours after the passive 
smoke challenge 15. Other experi- 
ments did not specifically address 
the impact of bronchial reactivity 
status 41, 42. 
It is to emphasize that our decision 
to focus the analyses on susceptible 
subgroups based on asthma status 
and sex, although suitable to ad- 
dress our question, has to be con- 
sidered a subgroup analysis, which 
showed an effect in a rather small 
subgroup. Thus, from a statistical 
point of view, the probability of a 
significant result does not cor- 
respond to the nominal p-value. 
Results among asthmatic women, 
however, were significant at a p- 
value of 0.01 (FEV1) and 0.008 
(FEF25-75 %) hence even under a 
very conservative adjustment for 
multiple testing, the findings among 
asthmatic women are unlikely to be 
due to chance. 
In contrast to the negative results 
among non-asthmatics, a previous 
analysis based on the SAPALDIA 
population 17showed significant as- 
sociations of total ETS exposure 
and prevalence of respiratory 
symptoms, uggesting symptoms to 
be a more sensitive measure than 
lung function. Although our results 
among non-asthmatics can not 
exclude that ETS exposure might 
induce small lung function decre- 
ments in healthy subjects 1, the 
impact of ETS at work, might be 
difficult to detect with epidemio- 
logical methods, unless exposure 
may be very strong. 
In summary, our study suggests 
that asthmatics are particularly sus- 
ceptible for adverse ffects of ETS 
exposure. However, the inherent 
methodologic limitations requires 
cautious interpretation. Further e- 
search should focus on susceptible 
subgroups, based on biologic mea- 
sures of susceptibility. Objective 
measures of ETS exposure profiles 
will allow to disentangle true and 
perceived exposure. This will lead 
to an adequate characterization f 
the impact of ETS among those at 
highest risk. 
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